AZD5718 phase IIa study to evaluate efficacy, safety and tolerability of oral AZD5718 in patients with coronary artery disease (CAD).

Trial Identifier: D7550C00003
Sponsor: AstraZeneca
NCTID:: NCT03317002
Start Date: October 2017
Primary Completion Date: April 2020
Study Completion Date: April 2020
Condition: Coronary Artery Disease

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English version
Danish Translation
Finnish Translation
Swedish Translation

Trial Locations

Country Location
Denmark Aarhus, Denmark, 8200
Denmark Frederiksberg, Denmark, 2000
Denmark Odense C, Denmark, 5000
Finland Kuopio, Finland, 70210
Finland Turku, Finland, 20520
Sweden GÖTEBORG, Sweden, 413 45
Sweden Lund, Sweden, 222 42
Sweden Stockholm, Sweden, 171 76
Sweden Uppsala, Sweden, 75185